티앤알바이오팹

246710KOSDAQ

47.8 / 100

Reference Date: 2026-09-08

Financial Score9.5 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 10.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

T&N Biofabrication focuses on regenerative medicine, bio-surgical solutions, and cosmetics, leveraging its 3D bioprinting systems, bioinks, and biodegradable scaffolds. The company is developing 3D organoids and cell therapies through long-term R&D while also advancing short-term revenue streams via bio-surgical solutions.

Number of Employees

82people

Average Salary

51.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.06Industry Average 1.200.0Point

3.4x industry avg (risky)

ROE

-127.09Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

202.46Industry Average 100.000.0Point

2.0x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲223.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲13.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -64.3% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
티앤알바이오팹, 자회사 성장 이어 본업도 가세…내년 흑자전환 전망...
티앤알바이오팹의 자회사 성장과 재생의료 분야의 성과로 내년 흑자전환 전망이 밝아짐.
Positive
티앤알바이오팹, 상반기 매출 46% ↑…적자폭도 대폭 축소
티앤알바이오팹의 상반기 매출이 전년 동기 대비 46% 증가하며, 특히 ECM 기반 바이오써지컬 제품군과 블리스팩의 성장으로 손익구조 개선이 이루어져 긍정적인 시장 반응을 보임.
Positive
티앤알바이오팹 "FDA 허가 발판…美 의료시장 본격 공략"
티앤알바이오팹의 FDA 허가 획득으로 미국 시장 진출이 본격화되어 긍정적인 성장 전망이 제시되었다.

Detailed Momentum

52-week position3.0Point

52w lower range (30%)

Current 2,220Won52-week high 4,53552-week low 1,194

1-month return1.0Point

1m -10.48% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral반기보고서 (2026.06)2026-08-31
Neutral[첨부정정]사업보고서 (2025.12)2026-08-27
Neutral[기재정정]파생상품거래손실발생2026-08-25
Neutral[기재정정]감사보고서제출 (2025사업연도)2026-08-25
Neutral[기재정정]사업보고서 (2025.12)2026-08-25